NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that the Company will be presenting at the Bear Stearns SMid-Cap Investor Conference and the 2006 Annual Stanford Growth Conference. Both presentations will take place in New York City on Tuesday, November 14, 2006.
Bear Stearns 2006 SMid-Cap Investor Conference: Corporate presentation will be delivered by Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, at 2:00 PM Eastern Time at the Bear Stearns World Headquarters. A live audio webcast of Mr. Weiss’ presentation will be available at http://cc.talkpoint.com/BEAR002/111406a_cy/?entity=keryx . An archived version of the webcast will be available following the conclusion of the live presentation.
2006 Annual Stanford Growth Conference: Corporate presentation will be delivered by Ronald C. Renaud, Jr., the Company’s Chief Financial Officer, at 8:30 AM ET at the St. Regis Hotel. A live audio webcast of Mr. Renaud’s presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KERX&item_id=1417466. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is Sulonex(TM), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Contact: Ronald C. Renaud, Jr. Chief Financial Officer 212 531-5965 rrenaud@keryx.com
Keryx Biopharmaceuticals, Inc.
CONTACT: Ronald C. Renaud, Jr., Chief Financial Officer of KeryxBiopharmaceuticals, Inc., +1-212-531-5965, rrenaud@keryx.com
